Haruta T, Kobayashi Y
Department of Pediatrics, Kobe City General Hospital.
Jpn J Antibiot. 1995 Feb;48(2):205-9.
SY5555 dry syrup (powder to be dissolved before use) was clinically used in pediatric patients. The following results were obtained: 1. The subjects were 6 pediatric patients including 1 case each with pharyngitis, tonsillitis, lacunar tonsillitis and impetigo contagiosa and 2 cases with scarlet fever. The drug was administered at a daily dose of 14.5-29.0 mg/kg divided into 3 dosages. The clinical results were excellent in 5 cases and good in 1 case with an efficacy rate of 100%. 2. Identified bacteria included 3 strains of Haemophilus influenzae, 2 strains of Streptococcus pyogenes and 1 strain of Staphylococcus aureus. Five strains were eradicated but 1 strain still remained with an bacteriological eradication rate of 83.3%. 3. No side effects were observed throughout the study period. In laboratory test results, elevated eosinophil count was observed in only 1 case. 4. Patients' compliance was good in general. 5. Based on the results mentioned above, the drug was considered to be a useful new oral antibiotic in the pediatric field.
SY5555干糖浆(使用前需溶解的粉末)已在儿科患者中进行了临床应用。获得了以下结果:1. 受试者为6名儿科患者,包括咽炎、扁桃体炎、陷窝性扁桃体炎和脓疱疮各1例,猩红热2例。药物的给药剂量为每日14.5 - 29.0毫克/千克,分3次给药。临床结果为5例优秀,1例良好,有效率为100%。2. 鉴定出的细菌包括3株流感嗜血杆菌、2株化脓性链球菌和1株金黄色葡萄球菌。5株细菌被根除,但仍有1株存在,细菌学根除率为83.3%。3. 在整个研究期间未观察到副作用。在实验室检查结果中,仅1例出现嗜酸性粒细胞计数升高。4. 患者的总体依从性良好。5. 根据上述结果,该药物被认为是儿科领域一种有用的新型口服抗生素。